search
Back to results

Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial

Primary Purpose

Dermatitis, Atopic, Child, Infant

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Fermented rice
Maltodextrins
Sponsored by
University of Milan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dermatitis, Atopic

Eligibility Criteria

6 Months - 36 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • diagnosis of moderate or sever atopic dermatitis using SCORAD

Exclusion Criteria:

  • acute rhino-conjunctivitis
  • acute asthma
  • autoimmune disease
  • chronic obstructive pulmonary disease
  • heart disease
  • renal disease
  • treatment with prebiotics 1 month before the enrolment
  • treatment with probiotics 1 month before the enrolment
  • treatment with antibiotics (undergoing)
  • treatment with systemic immune-modulators 1 month before the enrolment
  • treatment with local immune-modulators 1 month before the enrolment
  • acute or chronic infectious disease
  • known hypersensitivity to components of fermented rice flour

Sites / Locations

  • Pediatrics Department Ospedale dei Bambini V. BuzziRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Fermented rice

Maltodextrins

Arm Description

7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water

7 g of maltodextrins powder to be diluted in milk or water

Outcomes

Primary Outcome Measures

SCORAD change
The treatment will be stopped at 12 weeks

Secondary Outcome Measures

SCORAD change
The outcome will be evaluated also 4 weeks after the suspension of treatment

Full Information

First Posted
January 30, 2017
Last Updated
February 2, 2017
Sponsor
University of Milan
search

1. Study Identification

Unique Protocol Identification Number
NCT03042624
Brief Title
Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial
Official Title
Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
January 24, 2017 (Actual)
Primary Completion Date
May 31, 2017 (Anticipated)
Study Completion Date
May 31, 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Milan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This trial aims at evaluating the efficacy of a fermented rice flour for the treatment of atopic dermatitis (AD). The fermented rice flour, obtained from Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy), does not contain live bacteria. Lactobacillus paracasei CBA L74 belongs to the list of microorganisms with qualified presumption of safety compiled by the European Food Safety Authority (EFSA), is tested for the absence of antibiotic resistance genes in accordance with EFSA, and is genetically characterized by repetitive extragenic palindromic polymerase chain reaction. Using a repeated-measure cohort design, the investigators have recently shown that the administration of a fermented-rice flour obtained from Lactobacillus paracasei CBA L74 was associated with a decrease of the score for atopic dermatitis (SCORAD) in children with AD. The present randomized, double-blind, controlled trial is aimed at testing whether the fermented rice flour obtained from Lactobacillus paracasei CBA L74 is effective in reducing SCORAD in children with moderate to severe AD using placebo as comparator.
Detailed Description
Atopic dermatitis (AD), an itchy eczema with a chronic relapsing course, is the most common clinical manifestation of atopy in the first years of life. On the basis of the available knowledge, AD is produced by an alteration of the skin barrier which triggers an inflammatory reaction. Such reaction is characterized by an early phase with abundance of Th2 cytokines (IL-4, IL-5) and eosinophils and by a later phase with predominance of Th1 cytokines (IL-2, IL-12 and IFN-gamma). Emollients, possibly supplemented with ceramides, represent the first step of the treatment of AD. Corticosteroids are the most effective topical drugs. The use of topical immune-modulators (tacrolimus and pimecrolimus) offers an alternative to steroid therapy for long-term treatments. Severe cases require systemic therapy with steroids and cyclosporine and phototherapy with narrowband ultraviolet (UVB) and psoralen-ultraviolet A (PUVA) phototherapy. The use of probiotics for the treatment of AD has attracted much interest in recent years but the available data are not conclusive. Probiotic-like effects can be obtained from inactivated bacteria or isolated bacterial components so that an extensive definition of probiotics has been proposed as bacterial cells or bacterial components that have a beneficial impact on the health and well-being of guests. Using a repeated-measure cohort design, the investigators have recently shown that the administration of the fermented-rice flour obtained from Lactobacillus paracasei CBA L74 was associated with a decrease of SCORAD (score for atopic dermatitis) in children with AD. SCORAD is the most commonly employed indicator of AD activity and its minimal clinically important difference is known, making it a suitable metric for clinical trials. The fermented rice flour, obtained from Lactobacillus paracasei CBA L74 (Heinz Italia SpA, Latina, Italy), does not contain live bacteria. Lactobacillus paracasei CBA L74 belongs to the list of microorganisms with qualified presumption of safety compiled by the European Food Safety Authority (EFSA), is tested for the absence of antibiotic resistance genes in accordance with EFSA, and is genetically characterized by repetitive extragenic palindromic polymerase chain reaction. Pre-clinical studies have shown anti-inflammatory effects of matrices fermented with Lactobacillus paracasei CBA-L74 in terms of production of IL-10 and reduction of IL-12 in response to bacterial stimulation. Such pre-clinical data were obtained on dendritic cells, on intestinal biopsies and on murine models. The present randomized, double-blind, controlled trial is aimed at testing whether the fermented rice flour obtained from Lactobacillus paracasei CBA L74 is effective in reducing SCORAD in children with moderate to severe AD using placebo as comparator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dermatitis, Atopic, Child, Infant

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Parallel-arm, Randomized, Double-blind Controlled Trial
Masking
ParticipantCare ProviderOutcomes Assessor
Masking Description
Each treatment is numbered consecutively without any reference to the underlying randomization scheme, which is known only to the statistician who generated the list and to the technician who prepared the packages. The packages and their contents are indistinguishable.
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fermented rice
Arm Type
Experimental
Arm Description
7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
Arm Title
Maltodextrins
Arm Type
Placebo Comparator
Arm Description
7 g of maltodextrins powder to be diluted in milk or water
Intervention Type
Dietary Supplement
Intervention Name(s)
Fermented rice
Intervention Description
7 g of powder obtained from Lactobacillus paracasei CBA L74
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrins
Intervention Description
7 g of maltodextrins powder
Primary Outcome Measure Information:
Title
SCORAD change
Description
The treatment will be stopped at 12 weeks
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
SCORAD change
Description
The outcome will be evaluated also 4 weeks after the suspension of treatment
Time Frame
16 weeks
Other Pre-specified Outcome Measures:
Title
Fecal microbiota composition
Time Frame
12 weeks
Title
Cytokine profiling
Description
Measurement of peripheral IFN-gamma, IL-4, IL-5, IL-10, IL-12, IL-13, IL-18 and IL-31
Time Frame
12 weeks
Title
Peripheral immunophenotyping
Description
Measurement of peripheral Treg, central memory and effector and Th1/Th2/Th17 cells
Time Frame
12 weeks
Title
Total and specific IgE
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
36 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: diagnosis of moderate or sever atopic dermatitis using SCORAD Exclusion Criteria: acute rhino-conjunctivitis acute asthma autoimmune disease chronic obstructive pulmonary disease heart disease renal disease treatment with prebiotics 1 month before the enrolment treatment with probiotics 1 month before the enrolment treatment with antibiotics (undergoing) treatment with systemic immune-modulators 1 month before the enrolment treatment with local immune-modulators 1 month before the enrolment acute or chronic infectious disease known hypersensitivity to components of fermented rice flour
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Enza Carmina D'Auria, MD, PhD
Email
mailto:enzacarmina.dauria@asst-fbf-sacco.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gian Vincenzo Zuccotti, MD
Organizational Affiliation
Pediatrics Department Ospedale dei Bambini V. Buzzi Milano
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pediatrics Department Ospedale dei Bambini V. Buzzi
City
Milano
ZIP/Postal Code
20154
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Enza Carmina D'Auria, MD, PhD
Email
mailto:enzacarmina.dauria@asst-fbf-sacco.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
18408746
Citation
Elias PM, Steinhoff M. "Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008 May;128(5):1067-70. doi: 10.1038/jid.2008.88.
Results Reference
background
PubMed Identifier
9042042
Citation
Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol. 1997 Feb;99(2):179-85. doi: 10.1016/s0091-6749(97)70093-9.
Results Reference
background
PubMed Identifier
11069570
Citation
Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000 Nov;30(11):1604-10. doi: 10.1046/j.1365-2222.2000.00943.x.
Results Reference
background
PubMed Identifier
15863468
Citation
Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child. 2005 Sep;90(9):892-7. doi: 10.1136/adc.2004.060673. Epub 2005 Apr 29.
Results Reference
background
PubMed Identifier
8435513
Citation
Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31. doi: 10.1159/000247298.
Results Reference
background
PubMed Identifier
17325568
Citation
Agostoni C, Goulet O, Kolacek S, Koletzko B, Moreno L, Puntis J, Rigo J, Shamir R, Szajewska H, Turck D; ESPGHAN Committee on Nutrition. Fermented infant formulae without live bacteria. J Pediatr Gastroenterol Nutr. 2007 Mar;44(3):392-7. doi: 10.1097/01.mpg.0000258887.93866.69.
Results Reference
background
PubMed Identifier
24520333
Citation
Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, Rescigno M. Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivo. PLoS One. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.
Results Reference
background
PubMed Identifier
25757084
Citation
Beretta S, Fabiano V, Petruzzi M, Budelli A, Zuccotti GV. Fermented rice flour in pediatric atopic dermatitis. Dermatitis. 2015 Mar-Apr;26(2):104-6. doi: 10.1097/DER.0000000000000103. No abstract available.
Results Reference
background
PubMed Identifier
21951293
Citation
Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012 Jan;67(1):99-106. doi: 10.1111/j.1398-9995.2011.02719.x. Epub 2011 Sep 27.
Results Reference
background

Learn more about this trial

Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial

We'll reach out to this number within 24 hrs